Ludwig, Vera M. http://orcid.org/0000-0002-8475-8972
Sauer, Cathrin
Young, Allan H. http://orcid.org/0000-0003-2291-6952
Rucker, James http://orcid.org/0000-0003-4647-8088
Bauer, Michael http://orcid.org/0000-0002-2666-859X
Findeis, Hannelore
Ritter, Philipp http://orcid.org/0000-0003-4286-5830
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (tC2020_03_MED)
National Institute for Health Research (CS-2017-17- 007)
Deutsche Forschungsgemeinschaft
NIHR Biomedical Research Centre
European Commission
Novartis Pharma
Aristo
Hexal AG
Janssen Pharmaceuticals
Janssen-Cilag
Sunovion
GH Research
neuraxpharm
Sandoz
Shire International GmbH
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company
AstraZeneca
Eli Lilly and Company
H. Lundbeck A/S
Servier
LivaNova
Johnson and Johnson
Technische Universität Dresden
Article History
Accepted: 14 June 2021
First Online: 20 July 2021
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. This report represents independent research supported by Bundesministerium für Bildung und Forschung (BMBF) grant tC2020_03_MED (transCampus/TUD/BMBF), as well as the National Institute for Health Research (AHY and NIHR Clinician Scientist Award JR CS-2017-17- 007) and NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. PR received grants from the BMBF. The views expressed are those of the author(s) and not necessarily those of the BMBF, NHS, NIHR, or the Department of Health.
: AHY gave paid lectures and is on advisory boards for the following companies: AstraZeneca, Eli Lilly, Lundbeck, Sunovion, Servier, LivaNova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, and COMPASS and serves as a consultant to Johnson & Johnson and LivaNova. JR was paid by COMPASS Pathways to attend trial-related meetings and conferences to present the results of research using psilocybin and served as a paid consultant to Beckley PsyTech and Clerkenwell Health. MB has received institutional funding/grant support from Deutsche Forschungsgemeinschaft (DFG), BMBF, and the European Commission; has received speaker honoraria and/or travel compensation from Aristo, Hexal AG, Janssen Pharmaceutica NV, Janssen-Cilag, and Sunovion; has served on advisory boards or received honoraria consultancy from GH Research, Janssen-Cilag, neuraxpharm, Novartis, Sandoz, Shire International GmbH, Sumitomo Dainippon, Sunovion, and Takeda. The authors assert that the mentioned companies had no influence over the content of this article. VML, CS, HF, and PR have no conflicts of interest that are directly relevant to the content of this article.
: Our study complies with the Declaration of Helsinki and the study protocol was approved by the local ethics committee of the Medical Faculty of the Technical University Dresden (EK 263052019).
: Not applicable, as anonymized routine clinical data were used.
: The dataset can be obtained from the corresponding author upon reasonable request.
: SPSS Syntax codes are available upon request.
: All authors contributed to the study design and interpretation of the data. Material preparation and data collection were performed by VML and HF, and data analysis was performed by CS and VML. The first draft of the manuscript was written by VML; all authors commented on subsequent versions of the manuscript and approved the final manuscript and the decision to submit it for publication. All authors agree to be accountable for the data reported in the manuscript.